Taiwan Oncology small-molecule targeted therapies companies and pipeline landscape (November 2026) | Drugnews
At least 1 Taiwanese biotech companies are active in Oncology small-molecule targeted therapies, with 2 assets in development or on the market. The most advanced is PharmaEngine (4162)’s PEP07 (Phase 1; Acute Myeloid Leukemia). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
2 / 2
| PharmaEngine (4162) | 4162 | PEP07 | CHK1 inhibitor | Phase 1; recruiting | Acute Myeloid Leukemia; Lymphoma, Mantle-Cell | Not disclosed | 2025-07-31 | 2025-07-31 |
| PharmaEngine (4162) | 4162 | PEP08 | PRMT5 inhibitor | Phase 1 dose escalation ongoing | Advanced or metastatic MTAP-deficient solid tumors | Not disclosed | 2026-08-06 | 2026-08-06 |
No matches. Clear the search to show all rows.
Recent events
- Published source records PEP08: Phase 1 dose escalation ongoing. Source
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing Oncology small-molecule targeted therapies?
Currently, 1 companies are included: PharmaEngine (4162). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to Oncology small-molecule targeted therapies?
Taiwan-listed companies directly involved in Oncology small-molecule targeted therapies R&D, manufacturing or licensing include: PharmaEngine (4162). Compiled from public information; this is not investment advice.
Which Taiwanese Oncology small-molecule targeted therapies program is most advanced?
PharmaEngine (4162)’s PEP07 is at Phase 1 (Acute Myeloid Leukemia).
What is the latest important development in Taiwan’s Oncology small-molecule targeted therapies sector?
The latest record is 2026-08-06: PharmaEngine (4162) Published source records PEP08: Phase 1 dose escalation ongoing..
SourceHow often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.